Free radical scavengers: chemical concepts and clinical relevance

  • Michael Gassen
  • M. B. H. Youdim
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 56)


Free radicals are involved in the pathology of many CNS disorders, like Parkinson’s disease, Alzheimer’s disease, or stroke. This discovery lead to the development of many radical scavengers for the clinical treatment of neurodegenerative diseases. In this review, the different chemical concepts for free radical scavenging will be discussed: nitrons, thiols, iron chelators, phenols, and catechols. Especially catechols, like the naturally occurring flavonols, the synthetic drug nitecapone, or the endogenous catacholamines and their metabolites, are of great interest, as they combine iron chelating with radical scavenging activity. We present data on the radical scvenging activity of dopamine and apomorphine, which prevent lipid peroxidation in rat brain mitochondria and protect PC12 cells against H2O2-toxicity.


PC12 Cell Free Radical Scavenger Iron Chelator Semiquinone Radical Protect PC12 Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anghileri LJ, Maincent P, Cordova MA, Thouvenot P (1994) The role of ATP as a mediator in the action of iron complexes on cellular calcium homeostasis. Biol Trace Elem Res 46: 103–111PubMedCrossRefGoogle Scholar
  2. Ben-Shachar D, Riederer P, Youdim MBH (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s disease. J Neurochem 57: 1609–1614PubMedCrossRefGoogle Scholar
  3. Ben-Shachar D, Livne E, Spanier I, Zuk R, Youdim MBH (1993) Iron modulates neuroleptic-induced effects related to the dopaminergic system. Isr J Med Sci 29: 587–592PubMedGoogle Scholar
  4. Ben-Shachar D, Livne E, Spanier I, Leenders KL, Youdim MBH (1994) Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J Neurochem 62: 1112–1118PubMedCrossRefGoogle Scholar
  5. Benov LC, Benchev IC, Monovich OH (1990) Thiol antidotes effect on lipid peroxidation in mercury-poisoned rats. Chem Biol Interact 76: 321–332PubMedCrossRefGoogle Scholar
  6. Cadet JL, Ali S, Epstein C (1994) Involvement of oxygen-based radicals in metham-phetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann N Y Acad Sci 738: 388–391PubMedCrossRefGoogle Scholar
  7. Cao X, Phillis JW (1995) The free radical scavenger, α-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils. Free Radic Res 23: 365–370PubMedCrossRefGoogle Scholar
  8. Carney JM, Kindy MS, Smith CD, Wood K, Tatsuno T, Wu JF, Landrum WR, Floyd RA (1994) Gene expression and functional changes after acute ischemia: age-related differences in outcome and mechanisms. In: Hartmann A, Yatsu F, Kuschinsky W (eds) Cerebral ischemia and basic mechanisms. Springer, Berlin Heidelberg New York Tokyo, pp 301–311CrossRefGoogle Scholar
  9. Cerruti C, Sheng P, Ladenheim B, Epstein CJ, Cadet JL (1995) Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro. Clin Exp Pharmacol Physiol 22: 381–382PubMedCrossRefGoogle Scholar
  10. Cheng HY, Liu T, Feuerstein G, Barone FC (1993) Distribution of spin-trapping compounds in rat blood and brain: in vivo microdialysis determination. Free Radic Biol Med 14: 243–250PubMedCrossRefGoogle Scholar
  11. Chiueh CC, Krishna G, Tulsi P, Obata T, Lang K, Huang SJ, Murphy DL (1992) Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: Effects of MPP+. Free Radic Biol Med 13: 581–583PubMedCrossRefGoogle Scholar
  12. Ciuffi M, Gentilini G, Franchi Micheli S, Zilletti L (1992) D-penicillamine affects lipid peroxidation and iron content in the rat brain cortex. Neurochem Res 17: 1241–1246PubMedCrossRefGoogle Scholar
  13. Colton CA, Pagan F, Snell J, Colton JS, Cummins A, Gilbert DL (1995) Protection from oxidation enhances the survival of cultured mesencephalic neurons. Exp Neurol 132: 54–61PubMedCrossRefGoogle Scholar
  14. Ercal N, Treeratphan P, Hammond TC, Matthews RH, Grannemann NH, Spitz DR (1996) In vivo indices of oxidative stress in lead-exposed C57BL/6 mice are reduced by treatment with meso-2,3-dimercaptosuccinic acid or N-acetylcysteine. Free Radic Biol Med 21: 157–161PubMedCrossRefGoogle Scholar
  15. Esterbauer H (1980) Aldehydes of lipid peroxidation. In: McBrien DCH, Slater TF (eds) Free radicals, peroxidation, and cancer. Academic Press, London, pp 101–122Google Scholar
  16. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 32: 804–812PubMedCrossRefGoogle Scholar
  17. Ferrari G, Yan CY, Greene LA (1995) N-acetylcysteine (D-and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci 15: 2857–2866PubMedGoogle Scholar
  18. Folbergrova J, Zhao Q, Katsura K, Siesjö BK (1995) N-tert-butyl-α-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci U S A 92: 5057–5061PubMedCrossRefGoogle Scholar
  19. Froissard P, Monrocq H, Duval D (1997) Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal-like PC12 cells. Eur J Pharmacol 326: 93–99PubMedCrossRefGoogle Scholar
  20. Galey JB, Dumats J, Beck I, Fernandez B, Hocquaux M (1995) N,N′-bis-dibenzyl ethylenediaminediacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an “oxidative stress activatable” iron chelator in vitro. Free Radic Res 22: 67–86PubMedCrossRefGoogle Scholar
  21. Gancher ST, Nutt JG, Woodward WR (1995) Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord 10: 37–43PubMedCrossRefGoogle Scholar
  22. Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219–225PubMedCrossRefGoogle Scholar
  23. Gassen M, Gross A, Pinchasi B, Youdim MBH (1997) Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord in pressGoogle Scholar
  24. Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease. Eur J Pharmacol 208: 273–286PubMedCrossRefGoogle Scholar
  25. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793–807PubMedCrossRefGoogle Scholar
  26. Gerlach M, Riederer P, Youdim MBH (1996) Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Adv Neurol 69: 177–194PubMedGoogle Scholar
  27. Giovanni A, Liang LP, Hastings TG, Zigmond MJ (1995) Estimating hydroxyl radical content in rat brain using systematic and intraventricular salicylate: impact of methamphetamine. J Neurochem 64: 1819–1825PubMedCrossRefGoogle Scholar
  28. Götz ME, Kunig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37–122PubMedCrossRefGoogle Scholar
  29. Greene LA, Aletta JM, Rukenstein A, Green SH (1987) PC12 pheochromocytoma cells: culture, nerve growth factor treatment, and experimental exploitation. Methods Enzymol 147: 207–216PubMedCrossRefGoogle Scholar
  30. Haenen GR, Paquay JB, Korthouwer RE, Bast A (1997) Peroxynitrite scavenging by flavonoids. Biochem Biophys Res Commun 236: 591–593PubMedCrossRefGoogle Scholar
  31. Hall ED (1997) Antioxidant Therapeutic Strategies in CNS Disorders. In: Connor JR (ed) Metals and oxidative damage in neurological disorders. Plenum Press, New York, pp 325–339Google Scholar
  32. Hall ED, McCall JM (1993) Lazaroids: potent inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. In: Riederer P, Youdim MBH (eds) Iron in central nervous system disorders. Springer, Wien New York, pp 173–188CrossRefGoogle Scholar
  33. Hall ED, Andrus PK, Yonkers PA (1993) Brain hydroxyl radical generation in acute experimental head injury. J Neurochem 60: 588–594PubMedCrossRefGoogle Scholar
  34. Hallenbeck JM (1996) Significance of the inflammatory response in brain ischemia. Acta Neurochir [Suppl] Wien 66: 27–31Google Scholar
  35. Halliwell B, Gutteridge JMC (1985) Oxygen radicals and the nervous system. Trends Neurosci 8: 22–29CrossRefGoogle Scholar
  36. Haramaki N, Stewart DB, Aggarwal S, Kawabata T, Packer L (1995) Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Biochem Pharmacol 50: 839–843PubMedCrossRefGoogle Scholar
  37. Harley A, Cooper JM, Schapira AH (1993) Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson’s disease. Brain Res 627: 349–353PubMedCrossRefGoogle Scholar
  38. Hasinoff BB, Venkataram S, Singh M, Kuschak TI (1994) Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 24: 977–987PubMedCrossRefGoogle Scholar
  39. Hastings TG, Lewis DA, Zigmond MJ (1996) Reactive dopamine metabolites and neurotoxicity: implications for Parkinson’s disease. Adv Exp Med Biol 387: 97–106PubMedGoogle Scholar
  40. Hensley K, Carney JM, Steward CA, Tabatabaie T, Pye Q, Floyd RA (1997) Nitron-based free radical traps as neuroprotective agents in cerebral ischemia and other pathologies. In: Green AR, Cross AJ (eds) Neuroprotective agents in cerebral ischemia. Academic Press, San Diego, pp 299–317Google Scholar
  41. Hershko C (1994) Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol 7: 965–1000PubMedCrossRefGoogle Scholar
  42. Hershko C, Link G, Tzahor M, Pinson A (1993) The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 11: 207–214PubMedCrossRefGoogle Scholar
  43. Hess DC, Thompson Y, Sprinkle A, Carroll J, Smith J (1996) E-selectin expression on human brain microvascular endothelial cells. Neurosci Lett 213: 37–40PubMedCrossRefGoogle Scholar
  44. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S (1996) Design of orally active iron chelators. Acta Haematol 95: 6–12PubMedCrossRefGoogle Scholar
  45. Hoyt KR, Reynolds IJ, Hastings TG (1997) Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 143: 269–281PubMedCrossRefGoogle Scholar
  46. Hunter MIS, Nlemadim BC, Davidson DLW (1985) Lipid peroxidation production and antioxidant properties in plasma and cerebrospinal fluid of multiple sclerosis patients. Neurochem Res 10: 1645–1652PubMedCrossRefGoogle Scholar
  47. Janzen EG, Blackburn BJ (1968) Detection and identification of short-lived free radicals by an electron spin resonance trappind technique. J Am Chem Soc 90: 5909–5915CrossRefGoogle Scholar
  48. Janzen EG, Kotake Y, Hinton RD (1992) Stabilities of hydroxyl radical spin adducts of PBN-type spin traps. Free Radic Biol Med 12: 169–173PubMedCrossRefGoogle Scholar
  49. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MBH, Ben-Shachar D, Riederer P (1996) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson’s disease Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s disease. J Neural Transm [Suppl] 57: 1609–1614Google Scholar
  50. Kawabata T, Schepkin V, Haramaki N, Phadke RS, Packer L (1996) Iron coordination by catechol derivative antioxidants. Biochem Pharmacol 51: 1569–1577PubMedCrossRefGoogle Scholar
  51. Knuckey NW, Palm D, Primiano M, Epstein MH, Johanson CE (1995) N-acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats. Stroke 26: 305–310PubMedCrossRefGoogle Scholar
  52. Leenders KL, Antonini A, Schwarzbach R, Smith-Jones P, Reist H, Ben-Shachar D, Youdim MBH, Henn V (1994) Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. J Neural Transm [Suppl] 43: 123–132Google Scholar
  53. Lees AJ (1993) Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol 7: 121–128PubMedCrossRefGoogle Scholar
  54. Liehr JG (1997a) Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 6: 3–10PubMedCrossRefGoogle Scholar
  55. Liehr JG (1997b) Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ Health Perspect 105 [Suppl] 3: 565–569Google Scholar
  56. Liu J, Mori A (1993) Monoamine metabolism provides an antioxidant defense in the brain against oxidant-and free radical-induced damage. Arch Biochem Biophys 302: 118–127PubMedCrossRefGoogle Scholar
  57. Marx JJ, van Asbeck BS (1996) Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol 95: 49–62PubMedCrossRefGoogle Scholar
  58. McCay PB (1985) Vitamin E: Interactions with free radicals and ascorbate. Ann Rev Nutr 5: 323–340CrossRefGoogle Scholar
  59. Miller JW, Selhub J, Joseph JA (1996) Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 21: 241–249PubMedCrossRefGoogle Scholar
  60. Minotti G, Aust SD (1992) Redox cycling of iron and lipid peroxidation. Lipids 27: 219–226PubMedCrossRefGoogle Scholar
  61. Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P (1992) Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic Biol Med 13: 499–508PubMedCrossRefGoogle Scholar
  62. Morel I, Lescoat G, Cogrel P, Sergent O, Pasdeloup N, Brissot P, Cillard P, Cillard J (1993) Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol 45: 13–19PubMedCrossRefGoogle Scholar
  63. Oliver CN, Starke-Reed PE, Stadtman ER, Liu GJ, Carney JM, Floyd RA (1990) Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl Acad Sci U S A 87: 5144–5147PubMedCrossRefGoogle Scholar
  64. Olivieri NF (1996) Long-term therapy with deferiprone. Acta Haematol 95: 37–48PubMedCrossRefGoogle Scholar
  65. Packer L, Tritschler HJ, Wessel K (1997) Neuroprotection by the metabolic antioxidant α-lipoic acid. Free Radic Biol Med 22: 359–378PubMedCrossRefGoogle Scholar
  66. Panigrahi M, Sadguna Y, Shivakumar BR, Kolluri SV, Roy S, Packer L, Ravindranath V (1996) α-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res 717: 184–188PubMedCrossRefGoogle Scholar
  67. Pentikainen MO, Lindstedt KA, Kovanen PT (1995) Inhibition of the oxidative modification of LDL by nitecapone. Arterioscler Thromb Vasc Biol 15: 740–747PubMedCrossRefGoogle Scholar
  68. Riederer P, Sofic E, Rausch WD, Schmidt D, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 512–520CrossRefGoogle Scholar
  69. Sam EE, Verbeke N (1995) Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism. J Neural Transm PD Sect 10: 115–127CrossRefGoogle Scholar
  70. Sgaragli GP, Valoti M, Gorelli B, Fusi F, Palmi M, Mantovani P (1993) Calcium antagonist and antiperoxidant properties of some hindered phenols. Br J Pharmacol 110: 369–377PubMedCrossRefGoogle Scholar
  71. Shinobu LA, Beal MF (1997) The role of oxidative processes and metal ions in aging and Alzheimer’s disease. In: Connor JR (ed) Metals and oxidative damage in neurological disorders. Plenum Press, New York, pp 237–275Google Scholar
  72. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88: 10540–10543PubMedCrossRefGoogle Scholar
  73. Spear N, Aust SD (1995) Effects of glutathione on Fenton reagent-dependent radical production and DNA oxidation. Arch Biochem Biophys 324: 111–116PubMedCrossRefGoogle Scholar
  74. Stadtman ER (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 62: 797–821PubMedCrossRefGoogle Scholar
  75. Terland O, Flatmark T, Tangeras A, Gronberg M (1997) Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species. J Mol Cell Cardiol 29: 1731–1738PubMedCrossRefGoogle Scholar
  76. Trenam CW, Winyard PG, Morris CJ, Blake DR (1992) Iron promotes oxidative damage in rheumatic diseases. In: Lauffer RB (ed) Iron and human disease. CRC Press, Boca Raton, pp 395–418Google Scholar
  77. Vatessery GT (1997) Vitamin E: Neurochemical aspects and relevance to nervous system disorders. In: Connor JR (ed) Metals and oxidative damage in neurological disorders. Plenum Press, New York, pp 175–188Google Scholar
  78. Vimard F, Nouvelot A, Duval D (1996) Cytotoxic effects of an oxidative stress on neuronal-like pheochromocytoma cells (PC12). Biochem Pharmacol 51: 1389–1395PubMedCrossRefGoogle Scholar
  79. Wolz P, Krieglstein J (1996) Neuroprotective effects of α-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology 35: 369–375PubMedCrossRefGoogle Scholar
  80. Xiao G, van der Helm D, Hider RC, Rai BL (1996) Molecular modeling studies of a ferric hexadentate 3-hydroxy-2(lH)-pyridone complex and an analog by molecular mechanics, molecular dynamics, and free energy pertubation simulations. J Phys Chem 100: 2345–2352CrossRefGoogle Scholar
  81. Yamasaki Y, Itoyama Y, Kogure K (1996) Involvement of cytokine production in pathogenesis of transient cerebral ischemic damage. Keio J Med 45: 225–229PubMedCrossRefGoogle Scholar
  82. Youdim MBH, Lavie L, Riederer P (1994) Oxygen free radicals and neurodegeneration in Parkinson’s disease: a role for nitric oxide. Ann N Y Acad Sci 738: 64–68PubMedCrossRefGoogle Scholar
  83. Zhao Q, Pahlmark K, Smith ML, Siesjö BK (1994) Delayed treatment with the spin trap a-phenyl-N-tert-butyl nitrone (PBN) reduces infarct size following transient middle cerebral artery occlusion in rats. Acta Physiol Scand 152: 349–350PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • Michael Gassen
    • 1
  • M. B. H. Youdim
    • 2
  1. 1.Biomedical Research CNSMerck KGaADarmstadtFederal Republic of Germany
  2. 2.Department of Pharmacology, Eve Topf and National Parkinson’s Foundation Centers for Neurodegenerative DiseasesBruce Rappaport Family Research Institute, Faculty of MedicineTechnionIsrael

Personalised recommendations